Koyfin Home > Directory > Health Care > Acorda Therapeutics > Long-Term Debt

Acorda Therapeutics Long-Term Debt Chart (ACOR)

Acorda Therapeutics annual/quarterly Long-Term Debt from 2010 to 2020.
  • Acorda Therapeutics Long-Term Debt for the quarter ending June 06, 2020 was $157m a -123.09% decrease of -194m year over year
  • Acorda Therapeutics Long-Term Debt for the last 12 months ending June 06, 2020 was $157m a -123.09% decrease of -194m year over year
  • Acorda Therapeutics Annual Long-Term Debt for 2019 was $218m a -57.21% decrease of -125m from 2018
  • Acorda Therapeutics Annual Long-Term Debt for 2018 was $343m a 2.53% increase of 9m from 2017
  • Acorda Therapeutics Annual Long-Term Debt for 2017 was $334m a 3.12% increase of 10m from 2016
Other Cash Flow Metrics:
  • Acorda Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $78m a 23.00% increase of 18m year over year
  • Acorda Therapeutics Levered Free Cash Flow (FCF) for the quarter ending September 09, 2018 was $60m a 1.90% increase of 1m year over year
  • Acorda Therapeutics Total Revenue for the quarter ending December 12, 2018 was $69m a -53.52% decrease of -37m year over year
View Chart On Koyfin

Quarterly ACOR Long-Term Debt Data

06/2020$157m
03/2020$220m
12/2019$218m
09/2019$351m
06/2019$349m
03/2019$346m
12/2018$343m
09/2018$341m
06/2018$338m
03/2018$337m

Annual ACOR Long-Term Debt Data

2019$218m
2018$343m
2017$334m
2016$324m
2015$292m
2014$290m
2013$3m
2012$4m
2011$5m
2010$6m